Journal: Clinical immunology (Orlando, Fla.)

Article Title: Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells

doi: 10.1016/j.clim.2013.06.005

Figure Lengend Snippet: (A) CD1d expression in four medulloblastoma cell lines was examined by flow cytometry: staining with isotype control (tinted) or anti-hCD1d (open). (B) CD1d mRNA expression in four medulloblastoma cell lines was analyzed by RT-PCR using GADPH as an amplification control. (C) CD1d expression in primary tumors was assessed by IHC staining. Representative sections shown are from two CD1d-positive (upper pannel) and two CD1d-negative (lower pannel) of 20 analyzed tumors. Original magnification, X10. (D) CD1d mRNA expression was analyzed in 61 primary tumors by Taqman qRT-PCR and quantified using delta Ct method relative to the expression of HPRT1. DAOY and CHLA-255 cells were used as CD1d positive and negative controls, respectively.

Article Snippet: Immunohistochemistry Human medulloblastoma tissue array slides and normal brain paraffin tissue sections were purchased from Cybrdi, Inc. H&E staining was done following a standard hematoxylin and eosin staining protocol.

Techniques: Expressing, Flow Cytometry, Staining, Control, Reverse Transcription Polymerase Chain Reaction, Amplification, Immunohistochemistry, Quantitative RT-PCR